CD19 Directed Cytolytic Antibodies
- Name
- CD19 Directed Cytolytic Antibodies
- Accession Number
- DBCAT005691
- Description
Not Available
- Drugs
Drug Drug Description Inebilizumab A humanized anti-CD19 cytolytic monoclonal antibody for B-cell depletion in autoimmune conditions. Currently approved only for neuromyelitis optica spectrum disorder (NMOSD). - Drugs & Drug Targets
Drug Target Type Inebilizumab B-lymphocyte antigen CD19 target